Trial Profile

A Safety Study of the Administration of Mesenchymal Stem Cell Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AGLE 103 (Primary)
Indications Epidermolysis bullosa dystrophica
Focus Adverse reactions; Therapeutic Use
Sponsors Aegle Therapeutics

Most Recent Events

22 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Aug 2025.
14 Aug 2024 According to Aegle Therapeutics media release, Status changed from not yet recruiting to recruiting.
14 Aug 2024 According to Aegle Therapeutics media release, the company announced that the first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com